Back to Blog
Featured image for MeDucation AI blog article: HUS vs TTP: A Fellow's Guide to Telling Thrombotic Microangiopathies Apart at 2 AM

October 19, 2026

3 min read

HUS vs TTP: A Fellow's Guide to Telling Thrombotic Microangiopathies Apart at 2 AM


Disclaimer: Clinical content is intended for professional education and is not a substitute for independent clinical judgment or current institutional protocols.

The verdict: when you're paged about a hemoglobin drop, a severely low platelet count, and schistocytes on the smear, you do not wait for ADAMTS13 to come back before you act. Draw the ADAMTS13 activity and inhibitor level first, before any plasma or transfusion, then start therapeutic plasma exchange and corticosteroids without waiting for results[1]. Use the PLASMIC score at the bedside to estimate how likely this is immune TTP versus something else, because that number changes whether you also start caplacizumab before the ADAMTS13 result is back[1][2]. Everything else in this article is about sorting out which thrombotic microangiopathy (TMA) you're actually looking at once the first steps are handled.

Where a competitor's resource or a guideline body did something well, I'll say so.

Entity

ADAMTS13 activity

First-line treatment

Where it goes wrong if you misdiagnose it

Immune TTP (iTTP)

<10 IU/dL[1]

TPE + corticosteroids ± caplacizumab ± rituximab[1]

Delay in TPE is fatal; mortality was near 90% in the pre-plasma-exchange era[3]

Hereditary (congenital) TTP

<10 IU/dL[1]

Plasma infusion or TPE; no rituximab target

Missed in children/pregnancy where it accounts for a much larger share of cases[1]

Typical HUS (Shiga toxin-associated)

>10 IU/dL[1]

Supportive care; avoid antibiotics and antimotility agents[4]

Antibiotics can increase HUS risk in STEC infection[4]

Atypical HUS (complement-mediated)

>10 IU/dL[1]

Eculizumab or ravulizumab[5]

TPE alone does not address the complement pathway driving the disease

What should you actually do in the first hour when TMA is on the differential?

Draw the ADAMTS13 sample before you give any plasma product or start plasma exchange, then start treatment without waiting for the result[1]. The ISTH guideline panel, a multidisciplinary group of hematologists, an intensivist, a nephrologist, a clinical pathologist, a biostatistician, and patient representatives working with a McMaster methodology team, built its recommendations around exactly this sequencing problem[1]. Their first recommendation is explicit: acquire the ADAMTS13 sample, then start TPE and corticosteroids without waiting for results, and consider early caplacizumab before the ADAMTS13 activity comes back if your pretest probability is high[1].

Blood sample tube beside an infusion line started simultaneously

The reason for this is turnaround time. The panel considered an ADAMTS13 result back in under 72 hours "ideal" and 72 hours to 7 days "acceptable"[1]. In most hospitals you are deciding on TPE and caplacizumab in real time, long before that number exists. That's what the PLASMIC score is for.

References

  1. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura

  2. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study

  3. Overview of TTP • The Blood Project

  4. Recommendations for Diagnosis of Shiga Toxin--Producing Escherichia coli Infections by Clinical Laboratories

  5. FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome

Ready to pass your hematology-oncology boards?

Join MeDucation AI: board-style questions written and reviewed by practising hematologist-oncologists, with the explanations and study tools to turn a wrong answer into something you keep.

Start free trial

Share this article